Revolution Medicines is trading at $208.02, up 4.2% in pre-market on November 5 after its November 4 earnings release reported $197.6 million in RASONQUE revenue from roughly five weeks of U.S. sales, substantially above estimates. - More than 5,000 patients received commercial treatment, but the company cautioned that early revenue included finite patient groups and initial channel stocking, so it may not reflect the longer-term launch trajectory. - Biotech’s 2.08% pre-market gain offers additional sector support; pre-market volume was not provided.